Search

Your search keyword '"Tonietti G"' showing total 304 results
Start Over Author "Tonietti G"
304 results on '"Tonietti G"'

17. Physical human-robot interaction in anthropic domains: Safety and dependability

Author

Albu-Schäffer, Alin, Bicchi, A., Chatila, R., Luca De, A., Giralt, G., Hirzinger, Gerd, Mattone, R., Oriolo, G., Schiavi, R., Siciliano, B., Tonietti, G., Vendittelli, M., Villani, L., A., ALBU SCHAFFER, A., Bicchi, R., Chatila, A., DE LUCA, DE SANTIS, Agostino, G., Giralt, G., Hirzinger, Lippiello, Vincenzo, R., Mattone, R., Schiavi, Siciliano, Bruno, G., Tonietti, and Villani, Luigi

Published
2005

33. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study

Author

Giacomelli R, Paola Cipriani, Matucci Cerinic M, Fulminis A, Barattelli G, Pingiotti E, Di Franco M, Trotta A, Perricone R, Zazzeroni F, Alesse E, and Tonietti G

Subjects
rheumatoid arthritis, Adult, Male, Tumor Necrosis Factor-alpha, early rheumatoid arthritis, Gene Expression, In Vitro Techniques, Middle Aged, anti tnf, combination therapy, drug therapy, tnf alpha, Arthritis, Rheumatoid, Methotrexate, Antirheumatic Agents, Cyclosporine, Leukocytes, Mononuclear, Humans, Drug Therapy, Combination, Female, RNA, Messenger, Cells, Cultured
Abstract

To evaluate the ability of two different combination therapies with prednisone (PDN), methotrexate (MTX) and cyclosporine (CSA) to modulate both TNFalpha transcription and production in early rheumatoid arthritis (RA).24 patients with early RA received a step-down bridge therapy with MTX and PDN (group A). Twelve patients out of the 24 randomly received also CSA (group B). Blood samples and peripheral blood mononuclear cells (PBMC) were collected at different times. TNFalpha levels were measured both in sera and in PBMC supernatants. TNFalpha mRNA was assessed by use of RT-PCR.10 patients in group A and 9 in group B improved. At baseline, RA patients serum TNFalpha levels were increased compared to controls (p0.001) and did not correlate with clinical and serological parameters. These levels decreased within the first month of therapy in both groups, the lower levels being observed in the sera of CSA treated patients. After 30 days of therapy, TNFalpha levels in group B supernatants were significantly lower than those observed in group A, both after 24 and 48 hours of PHA stimulation (p0.03 and p0.05 respectively). TNFalpha mRNA levels never differed between patients and controls, independently of both the clinical picture and the assigned therapy.The addition of CSA to a treatment regimen of PDN + MTX lowers TNFalpha production in vitro without decreasing TNFalpha mRNA expression. This effect could help to induce early immunosoppressive and therapeutic effects during RA.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results